Jump to content

Thai Disease Control Dept insists Favipiravir is effective in treating COVID-19


webfact

Recommended Posts

7F993AF6-2874-45F7-B6CA-E73E3428C7CD.jpg

 

The Disease Control Department has asked critics not to undervalue the Favipiravir anti-viral medication, as it insists that the drug is efficacious in the treatment of COVID-19.

 

Dr. Opart Karnkawinpong, the department’s director-general, cited a Thai study on the use of Favipiravir, jointly conducted by the Clinical Research Centre of the Faculty of Medicine at Siriraj hospital, the Bamrasnaradura Institute of Infectious Diseases, the Department of Disease Control and the Medical Sciences Department.

 

Keep up to date with all things Thailand - Join our daily ASEAN NOW Thailand Newsletter - Click to subscribe

 

He said today (Saturday) that the study was conducted on two groups of COVID-19 patients. The first 62 patients were administered 1,800 milligrams of Favipiravir twice day a day on the first day, followed by 800 milligrams twice a day for four days. The second group of 31 patients were not given Favipiravir.

 

Discover Cigna’s range of health insurance solutions created for expats and local nationals living in Thailand - click to view

 

Full story: https://www.thaipbsworld.com/thai-disease-control-dept-insists-favipiravir-is-effective-in-treating-covid-19/

 

Logo-top-.png
-- © Copyright Thai PBS 2022-03-21
 

- Aetna offers a range of visa-compliant plans that meet the minimum requirement of medical treatment, including COVID-19, up to THB 3m. For more information on all expat health insurance plans click here.

 

  • Haha 2
Link to comment
Share on other sites

Like there Sinovac and Sinopharm deals they've probably taken ages to work out kickbacks.

 

They don't want to start that process again with a new and better drug.

 

They've probably already spent the money.

 

  • Like 2
Link to comment
Share on other sites

11 hours ago, webfact said:

He said today (Saturday) that the study was conducted on two groups of COVID-19 patients. The first 62 patients were administered 1,800 milligrams of Favipiravir twice day a day on the first day, followed by 800 milligrams twice a day for four days. The second group of 31 patients were not given Favipiravir.

With tens of thousands new Covid cases daily (and that's just the official count!), you'd think they should have been able to conduct a somewhat more sizable study. 93 people, really?

  • Like 1
Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Recently Browsing   0 members

    • No registered users viewing this page.



×
×
  • Create New...